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Although oligodendrocytes constitute a significant proportion of cells in the central nervous system (CNS), little is known
about their intermediary metabolism. We have, therefore, characterized metabolic functions of primary oligodendrocyte pre-
cursor cell cultures at late stages of differentiation using isotope-labelled metabolites. We report that differentiated oligoden-
drocyte lineage cells avidly metabolize glucose in the cytosol and pyruvate derived from glucose in the mitochondria. The
labelling patterns of metabolites obtained after incubation with [1,2-13C]glucose demonstrated that the pentose phosphate
pathway (PPP) is highly active in oligodendrocytes (approximately 10% of glucose is metabolized via the PPP as indicated by
labelling patterns in phosphoenolpyruvate). Mass spectrometry and magnetic resonance spectroscopy analyses of metabolites
after incubation of cells with [1-13C]lactate or [1,2-13C]glucose, respectively, demonstrated that anaplerotic pyruvate carboxy-
lation, which was thought to be exclusive to astrocytes, is also active in oligodendrocytes. Using [1,2-13C]acetate, we show
that oligodendrocytes convert acetate into acetyl CoA which is metabolized in the tricarboxylic acid cycle. Analysis of label-
ling patterns of alanine after incubation of cells with [1,2-13C]acetate and [1,2-13C]glucose showed catabolic oxidation of
malate or oxaloacetate. In conclusion, we report that oligodendrocyte lineage cells at late differentiation stages are metabo-
lically highly active cells that are likely to contribute considerably to the metabolic activity of the CNS.
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Introduction
Oligodendrocytes make up a large proportion of the cellsin the central nervous system (CNS). Although oligo-
dendrocytes are vulnerable to low energy conditions (Lyons
and Kettenmann, 1998; Yan and Rivkees, 2006), their meta-
bolic properties, including their glucose metabolism, have not
been investigated in depth (Amaral et al., 2013). In contrast,
the metabolic interactions between neurons and astrocytes,
have received considerable attention since their discovery in
the 1970s (van den Berg and Garfinkel, 1971). Specifically,
the shuttling of glutamine–glutamate–g-Aminobutyric acid
(GABA) between astrocytes and neurons is thought to be fun-
damentally important for neuronal function. Because neurons
themselves are unable to generate essential precursors of gluta-
mate, GABA, and aspartate, they depend on the supply of
glutamine as a precursor from astrocytes for the production
of neurotransmitters (glutamate in 90% of the synapses, and
GABA in 5%) (Attwell and Laughlin, 2001). In this context,
glucose plays a central role as the key molecular building
block that is used to synthesize glutamate, GABA, and
aspartate.
Glucose is primarily metabolized to pyruvate via glycoly-
sis in the cytosol. Stepwise conversion of a single glucose mole-
cule into two pyruvate molecules generates two molecules of
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Adenosine triphosphate (ATP) . These reactions are not oxygen
dependent. Glucose metabolism can also take an alternative
route via a biosynthetic pathway termed pentose phosphate path-
way (PPP). This complex detour bypasses several steps of gly-
colysis. In the first, oxidative phase of the PPP, NADP1 is
converted into Nicotinamide adenine dinucleotide phosphate
(NADPH). NADPH acts as a reducing agent that may partici-
pate in lipid and steroid synthesis or in the regeneration of glu-
tathione and thioredoxin, which are involved in the cell’s
defense mechanism against oxidative stress. In the second phase
of the PPP, 5-carbon sugars are nonoxidatively synthetized. The
PPP joins the glycolytic pathway at the level of glyceraldehyde-
3-phosphate (GA3P) and fructose-6-phosphate (fructose-6P).
Fructose-6P is subsequently converted into pyruvate, which con-
stitutes the endpoint of both glycolysis and the PPP.
In the presence of oxygen, the pyruvate produced by
glycolysis or by the PPP can be converted to acetyl CoA by
the pyruvate dehydrogenase (PDH) complex, and subse-
quently metabolized in the mitochondrial tricarboxylic acid
(TCA) cycle, to further produce ATP via coupling to the
mitochondrial electron transport chain. Alternatively, pyruvate
can be (reversibly) converted into lactate in the cytosol, which
results in the production of NAD1 from NADH. Net syn-
thesis of TCA cycle intermediates and related compounds,
including glutamate and glutamine, depend on anaplerotic
replenishment of intermediates in the TCA cycle. In the
brain, this is mediated by pyruvate carboxylase (PC; Patel,
1974). Pyruvate carboxylation was shown to be absent in
neurons, but present in astrocytes (Cesar and Hamprecht,
1995; Hertz et al., 1980; Shank et al., 1985; for review, see
Sonnewald and Rae, 2010). Consequently, neurons are
thought to depend on astrocytes as an external source of glu-
tamine for the production of neurotransmitters. Conversion of
pyruvate by PC generates a “new” molecule of oxaloacetate.
Oxaloacetate may subsequently condense with acetyl CoA to
synthesize the TCA cycle intermediate citrate, which, after se-
veral steps, is converted to a-ketoglutarate, from which gluta-
mate can be formed by transamination or deamination. In a
subsequent step, glutamine synthetase, which is known to be
expressed in astrocytes (Martinez-Hernandez et al., 1977; Nor-
enberg and Martinez-Hernandez, 1979), is able to convert glu-
tamate into glutamine (see Fig. 1 in Amaral et al., 2013).
In the gray matter, glutamate, released from neuronal
synapses during glutamatergic neurotransmission, is mainly
taken up by astrocytes (Gegelashvili and Schousboe, 1997,
1998). The drain of glutamate from signalling neurons is sub-
sequently compensated by a reverse flow of glutamine from
astrocytes back to the neurons. This cross flow of glutamate
and glutamine is often referred to as the glutamate—glutamine
cycle (McKenna et al., 2012; see Fig. 1 in Amaral et al., 2013).
Because glutamine released by astrocytes also functions as a
precursor for the production of the inhibitory neurotransmitter
GABA via conversion to glutamate (Reubi et al., 1978; Sonne-
wald et al., 1993b), metabolic interactions between astrocytes
and neurons are thought to consist of a glutamate–glutamine
and a glutamine–glutamate–GABA cycle.
How can oligodendrocytes contribute to the metabolic
interactions in the CNS? We have argued that, instead of being
restricted to closed-loop interactions between astrocytes and
neurons, intercellular shuttling of metabolites may occur
between all three major cell groups of the CNS: neurons,
astrocytes, and oligodendrocytes (Amaral et al., 2013). The
limited understanding of the metabolic role of oligodendro-
cytes in the brain was further highlighted in two recent studies,
FIGURE 1: Purity of the primary cultures of rat oligodendrocytes. Oligodendrocyte precursor cells were isolated from mixed glia cultures
and cultured in Sato’s medium10.05% FCS to induce differentiation. At day 1 of differentiation, more than 93% of the cells expressed
the oligodendroglial lineage marker O4 (A) and at 5 days of differentiation, approximately 65% of the cells expressed myelin basic pro-
tein (MBP), a marker of mature oligodendrocytes (B). Scale bars, 50 mm. [Color figure can be viewed in the online issue, which is avail-
able at wileyonlinelibrary.com.]
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which, for the first time, proposed a link between glycolytic
metabolism in oligodendrocytes and axonal integrity and func-
tion (Funfschilling et al., 2012; Lee et al., 2012).
The aim of this study was to elucidate basic metabolic
pathways for glucose catabolism and the anaplerotic reple-
nishment of TCA cycle intermediates in oligodendrocytes.
For this purpose, we incubated primary cultures enriched for
mature oligodendrocytes in medium containing [1,2-13C]glu-
cose, [1,6-13C]glucose, [1-13C]lactate, or [1,2-13C]acetate and
analyzed cell extracts and medium using mass spectrometry or
nuclear magnetic resonance (NMR) spectroscopy. We found
that oligodendrocytes have extensive PPP activity. Further-
more, oligodendrocytes were able to anaplerotically replenish
the TCA cycle, via pyruvate carboxylation, and catapleroti-
cally recycle pyruvate. Our data also show that oligodendro-
cytes are able to convert [1,2-13C]acetate into acetyl CoA.
Our results establish hallmarks of the cellular metabolism of
oligodendrocytes under physiological conditions. They may
also be useful for future studies investigating altered oligoden-
drocyte function and injury in diseases that involve glutamate
toxicity and impaired mitochondria function, including, for
example, hypoxic–ischemic damage, and multiple sclerosis
(MS; Kostic et al., 2013; Mifsud et al., 2014; Pitt et al.,
2000; Simonishvili et al., 2013).
Materials and Methods
Materials
Cell culture reagents were purchased from Sigma (Dorset, UK)—Dul-
becco’s modified eagle’s medium (DMEM), minimum essential medium
eagle (MEM), L-glutamine, poly-L-lysine (PLL), papain—or Life Tech-
nologies (Paisley, UK)—fetal bovine serum (FBS), penicillin-
streptomycin (pen-strep), trypsin-Ethylenediaminetetraacetic acid
(EDTA), phosphate buffered saline (PBS). 13C-labelled compounds
were obtained from Cambridge Isotope Laboratories, MA. The mass
spectrometry derivatization reagents MTBSTFA (N-methyl-N-(tert-
butyldimethylsilyl) trifluoroacetamide), MSTFA (N-Methyl-N-(trimeth-
ylsilyl) trifluoroacetamide) and the t-BDMS-Cl (tert-butyldimethyl-
chlorosilane) were purchased from Regis Technologies (Morton Grove,
IL). All other chemicals were of the purest grade available from Sigma
(Dorset, UK).
Preparation of Primary Oligodendrocyte
Precursor Cell Cultures
Primary mixed glia cultures were isolated from neonatal Sprague
Dawley rat (postnatal day 0–2) forebrains following a standard pro-
tocol (Baer et al., 2009). Pups were euthanized according to
“Schedule 1” regulations from the Home Office Animal Procedures
Committee UK. Cells were cultured for 10–15 days in DMEM sup-
plemented with 10% FBS, 1% pen-strep, and 4 mM glutamine, and
kept under a humidified atmosphere at 378C and 7% CO2. Oligo-
dendrocyte precursor cells (OPCs) were subsequently isolated using a
step-based shake-off protocol and cultured in Sato’s medium on
PLL-coated plates (Baer et al., 2009). To induce differentiation,
OPCs were cultured in Sato’s medium supplemented with 0.5% fetal
calf serum (FCS). The cell culture medium was replaced by fresh
medium at day two of differentiation. For all in vitro experiments,
only cultures with >93% purity (determined based on O4 immuno-
staining) were used (Fig. 1). Quantification of the number of glial
fibrillary acidic protein (GFAP)-positive cells after 5 days of differen-
tiation, indicated that astrocytes comprised 7–10% of total cells
(data not shown).
Preparation of Rat Cortical Astrocyte Cultures
Astrocytes were prepared from the same mixed glia cultures used for
OPC isolation, following an adapted protocol described in Amaral
et al. (2014). After the shake-off (which eliminates microglia and
most oligodendrocytes from the cultures), the remaining cells, highly
rich in proliferative astrocytes, were seeded into new T75 flasks (1:3
dilution) using DMEM supplemented with 10% (v/v) FBS, 4 mM
glutamine, and 1% (v/v) pen-strep and allowed to reach confluence
(approx. 5–7 days). Then, cells were collected with trypsin-EDTA
and seeded in 6 well plates at a density of 5 3 104 cells/well for the
[1-13C]lactate experiments. Experiments were performed when cells
reached confluence.
Incubations with 13C-Labelled Compounds
Mature OPC cultures (after 5 days in differentiation medium) were
cultured in 6 well plates at a cell density of 4 3 105 cells/well. Prior
to incubation, cells were washed once with PBS and incubated with
2 mL Sato’s medium prepared from a glucose, glutamine, and
pyruvate-free DMEM (Sigma D5030) supplemented with 0.5%
FCS and 2 mM [1,6-13C]glucose, 2 mM [1,2-13C] glucose1 1 mM
glutamine, 2 mM [1,2-13C]acetate1 1 mM glutamine, or 5 mM
[1-13C]lactate1 2 mM glucose1 1 mM glutamine for 24 h. Astro-
cytes were washed once with PBS and incubated with 2 mL DMEM
(Sigma D5030) supplemented with 4 mM [1-13C]lactate1 2 mM
glucose, 1 mM glutamine, 1% pen-strep, and 1% FBS for 24 h.
Samples of medium were collected before and after the incubation
period and subsequently analyzed by mass spectrometry. After the
24 h incubation period, cells were washed twice with cold PBS and
the intracellular metabolites extracted with 70% ethanol (Amaral
et al., 2014). Astrocyte cultures were also incubated for 24 h in
2 mL DMEM containing 2 mM D-glucose, 1 mM glutamine, 1%
pen-strep, and 1% FBS in order to determine glucose consumption
and lactate production rates after 24 h. Experiments were performed
on 9–12 samples, which derived from a minimum of three inde-
pendently generated cultures.
Immunocytochemistry
OPCs were seeded on PLL-coated glass coverslips on 24 well plates
(7 3 104 cells/well) and fixed after 5 days of differentiation with
4% paraformaldehyde. Cells were stained with an anti-O4 mouse
monoclonal antibody (1:200; Sigma, Dorset, UK), anti-myelin basic
protein (MBP) rat polyclonal antibody (1:300; Merck Millipore,
Hertfordshire, UK), and anti-GFAP rabbit polyclonal antibody (1/
500; Dako, Glostrup, Denmark). Secondary antibodies conjugated
with Alexa Fluor 488 and Alexa Fluor 555 were used to visualize
positive cells (1:500; Life Technologies, Paisley, UK). Following
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immunocytochemistry, cells were mounted with Prolong gold anti-
fade mounting medium (Life Technologies, Paisley, UK). To assess
purity and differentiation of oligodendroglia lineage cells in the cul-
tures, the percentage of O4-, MBP-, and GFAP-positive cells relative
to >100 40,6-diamidino-2-phenylindole (DAPI)-stained nuclei per
experiment in randomly selected eye fields was determined. Cells
were visualized and digitized at ambient temperature on an LSM
700 confocal microscope (Zeiss, Thornwood, NJ) at 203 magnifica-
tion using Zen Application software (Zeiss).
Assessment of Cell Viability
To assess cell viability under the different experimental conditions,
the Dead EndTM Fluorometric Terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL) System Kit (Promega, Madison,
WI) was used according to the manufacturer’s instructions. Images
of the stained cells were obtained using an INCell Analyzer 2200
Imaging System (GE Healthcare Life Sciences) and processed using
the ImageJ software. Ten random fields were acquired per condition
using a magnification of 203. Image analysis and quantification was
performed on CellProfiler, a cell image analysis software developed
by the BROAD Institute. The number of DAPI-positive nuclei (total
number of cells) and the number of TUNEL-positive nuclei were
automatically counted, and the results presented as percentage of
apoptotic nuclei of all DAPI-positive nuclei.
Glucose and Lactate Analyses
Glucose and lactate levels in the cell culture medium were analyzed
at the Core Biochemical Assay Laboratory, Clinical Biochemistry,
Addenbrooke’s Hospital using automated assays on a Siemens
Dimension RxL analyser. The rate of glucose and lactate net change
relative to cells over time (mmol/106 cells/24 h) was calculated by
subtracting the value measured at the end of the experiment
(T5 24 h) from the one measured in a sample of medium collected
at the onset of the incubation, and dividing the resulting value by
the amount of cells in each experiment, multiplied by the experi-
mental volume (2 mL). For oligodendrocyte cultures, the cell num-
ber considered was the cell number at plating since these cells do
not proliferate. For astrocyte cultures (which proliferate to some
extent), the cell number considered was determined at the end of
the experiment, after collection of cells from two sample wells using
trypsin-EDTA.
High Performance Liquid Chromatography
High performance liquid chromatography (HPLC) was used to
quantify the total amounts of amino acids in samples of cell extracts
and medium. Samples were lyophilized and resuspended in 0.01M
HCl and subsequently derivatized with o-phtaldialdehyde (Geddes
and Wood, 1984) using an automated method prior to injection
into the HPLC column. The amino acid components were separated
with a ZORBAX SB-C18 (4.6 3 150 mm, 3.55 lm) column from
Agilent Technologies (Palo Alto, CA). As eluents, a mixture of
50 mM sodium phosphate buffer (pH 5.9) with 2.5% tetrahydrofu-
rane and a mixture of methanol (98.75%) with tetrahydrofurane
(1.25%) were used. The samples were analyzed using a Hewlett
Packard 1100 System (Agilent Technologies, Palo Alto, CA) with
fluorescence detection. Amino acid concentrations were determined
by comparison to a calibration curve of standard solutions of amino
acids run after every 12 samples (Amaral et al., 2014).
Gas Chromatography–Mass Spectrometry
For analysis of percent enrichment of 13C in lactate, amino acids
(alanine, aspartate, glutamate, and glutamine) and TCA cycle inter-
mediates (citrate and malate) after incubation with different 13C-
labelled substrates, cell extracts, and samples of medium were lyophi-
lized and resuspended in 0.01M HCl. To move the metabolites of
interest into the organic phase in their acid form, the pH was
adjusted to pH< 2 with 6M HCl. Samples were dried under atmos-
pheric air (508C), and metabolites were derivatized with MTBSTFA
in the presence of 1% t-BDMS-Cl (Mawhinney et al., 1986). The
protocol used for analysis of the glycolytic intermediates phosphoe-
nolpyruvate (PEP) and 3-phosphoglycerate (3PG) was based on the
protocol reported by Hofmann et al. (2008). Derivatization was per-
formed using a mixture of MSTFA1 1% trimethylchlorosilane and
acetonitrile. The samples were analyzed on an Agilent 6890 gas
chromatograph connected to an Agilent 5975B mass spectrometer
(Agilent Technologies, Palo Alto, CA). The parent ion (M) and
atom percent excess for one 13C atom (M11) values for 3PG, PEP,
alanine, aspartate, lactate, citrate, and glutamate were calculated
from the gas chromatography-mass spectrometry (GC–MS) data
using the MassHunter software supplied by Agilent (Agilent Tech-
nologies, Palo Alto, CA) and correcting for the naturally abundant
13C using nonenriched standards (Biemann, 1962).
13C And 1H NMR Spectroscopy
13C NMR spectroscopy was used to identify the synthesis of particu-
lar labelled isotopologues from [1,2-13C]glucose metabolism due to
the ability of this technique to distinguish between the different car-
bon positions that are labelled in one molecule. For example, 13C
NMR spectroscopy enabled to distinguish between the presence of
[2,3-13C]glutamate (synthesized via pyruvate carboxylation) and
[1,2-13C]glutamate (synthesized via PDH; see below for further
details). In contrast, GC–MS is a more sensitive method that pro-
vides information about 13C enrichment above natural abundance
but lacks the specificity of NMR spectroscopy, as it does not provide
information about the location of the 13C label. GC–MS, as applied
in this study, only enables to distinguish between species that have a
different number of 13C-labelled carbons. All NMR samples were
analyzed using a QCI CryoProbeTM 600 MHz (for proton) ultra-
shielded Plus magnet (Bruker BioSpin GmbH, Reinstetten, Ger-
many). 1H NMR spectra were acquired using a pulse angle of 908,
12 kHz spectral width with 66 data points, acquisition time of
2.66 s, relaxation delay of 10 s and 128 scans. These spectra were
used to quantify the amount of glutamate for correction of natural
abundance of [4-13C]glutamate (to be used in the calculation of con-
tribution of the PPP to [4-13C]glutamate synthesis). Proton
decoupled 13C NMR spectra were obtained on the same instrument
using a 308 pulse angle and 30 kHz spectral width with 98,000 data
points using an acquisition time of 1.65 s and a relaxation delay of
0.5 s. The number of scans needed to obtain an appropriate signal
to noise ratio was 210,000. TopSpinTM 3.0 software (Bruker BioSpin
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GmbH, Reinstetten, Germany) was used for acquisition, integration,
and quantification. Relevant peaks in the spectra were assigned and
quantified from the integrals of the peaks using ethylene glycol as an
internal standard with known amount of 13C. Corrections for natu-
ral abundance as well as nuclear Overhauser enhancement and rela-
xation effects, relative to the internal standard, were applied to all
relevant integrals from 13C spectra.
Statistical Analysis
Statistical analysis was conducted using unpaired two-tailed student’s
t-tests (confidence interval5 95%).
Results
Characterization of Late Differentiation-Stage
Oligodendrocyte Lineage Cells In Vitro
To study metabolic reactions in mature oligodendroglia cul-
tures, highly enriched primary rat OPCs (Fig. 1A) were diffe-
rentiated in Sato’s differentiation medium. At 5 days of
differentiation, the cells displayed the characteristically
branched morphology of late oligodendrocyte lineage cells
with approximately 65% of the cells expressing MBP (Fig.
1B). To investigate the relative activity of different metabolic
pathways in mature oligodendrocytes, cells were incubated
with one of the following 13C-labelled substrates: [1,6-13C]glu-
cose, [1,2-13C]glucose, [1-13C]lactate, or [1,2-13C]acetate.
Differentiated Oligodendrocyte Lineage Cells
Display a Significant Activity of the PPP
To investigate the relative activity of the glycolytic pathway ver-
sus the PPP, [1,2-13C]glucose was added to the medium
(Brekke et al., 2014; Dusick et al., 2007). Following 24 h of
incubation, cell extracts were collected and analyzed using
GC–MS and 13C and 1H NMR spectroscopy. If [1,2-13C]glu-
cose is metabolized via the glycolytic pathway, [2,3-13C]3PG,
[2,3-13C]PEP, and [2,3-13C]pyruvate are formed (Fig. 2A).
[2,3-13C]pyruvate can enter the mitochondria to be converted
into [1,2-13C]acetyl CoA. Condensation of [1,2-13C]acetyl
CoA with unlabelled oxaloacetate leads to the formation of the
TCA cycle intermediate [1,2-13C]citrate and then, following
several steps, a-[4,5-13C]ketoglutarate, which is subsequently
converted into [4,5-13C]glutamate. [1,2-13C]glucose metabo-
lism via the PPP gives rise to [3-13C]3PG, [3-13C]PEP,
[3-13C]pyruvate, and [2-13C]acetyl CoA (Fig. 2B). [2-13C]ace-
tyl CoA can then be converted into [4-13C]glutamate via the
TCA cycle (Fig. 2B).
Because PEP and 3PG are localized downstream of the
intersection between glycolysis and the PPP, their 13C isoto-
pologues can be used to calculate the ratio between glycolysis
and the PPP. Analysis of PEP and 3PG enables detection of
isotopologues that derive from the re-entry of metabolic inter-
mediates (fructose-6P and GA3P) into glycolysis from the
PPP. The intermediates of the PPP lose the 13C in the C1
position via decarboxylation of [1,2-13C]gluconate-6-phos-
phate by 6-phosphogluconate dehydrogenase and 1/3 of the
molecules will re-enter glycolysis with only one labelled
(M11) carbon instead of two (M12)—see Fig. 2 and Brekke
et al. (2012) for further details. Based on GC–MS results, the
FIGURE 2: Evidence of pentose phosphate pathway (PPP) activity
in mature oligodendrocytes in culture after incubation with
[1,2-13C]glucose. Labelling patterns derived from [1,2-13C]glucose
metabolism via glycolysis (A) and the PPP (B). The % enrichment of
13C in M11 and M12 isotopologues for 3PG and PEP was deter-
mined using GC–MS analysis of cell extracts after 24-h incubation
with [1,2-13C]glucose. The ratio shown in (C) between M11 (label-
ling from the PPP) and M12 (labelling from glycolysis) enables to
estimate the contribution of the PPP versus glycolysis to the forma-
tion of the glycolytic intermediates 3PG and PEP in mature oligo-
dendrocyte (mean6 s.e.m.; n53). (D) 13C nuclear magnetic
resonance spectrum of a cell extract from cultures incubated in
medium containing [1,2-13C]glucose for 24 h. The C-4 region of
glutamate at 34.5 ppm (GLU) is shown. The doublet peak repre-
sents [4,5-13C]glutamate ([4,5-13C]GLU) which derives from glucose
metabolism via glycolysis only. The singlet peak corresponds to
[4-13C]glutamate ([4-13C]GLU) which is produced after glucose
metabolism via the PPP. Abbreviations: 3PG, 3-phosphoglycerate;
GLU, glutamate; PEP, phosphoenolpyruvate; PDH, pyruvate dehy-
drogenase; M11, parent ion with one 13C atom; M12, parent ion
with two 13C atoms. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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M12/M11 ratios of PEP and 3PG were calculated, indicat-
ing that 10–15% of glucose is metabolized via the PPP in
mature oligodendrocytes (Fig. 2C). Of note, this ratio is
likely to underestimate the contribution of the PPP (for
details, see Brekke et al., 2012).
An alternative way to investigate the relative contribu-
tion of glycolysis and PPP to glucose metabolism is to apply
13C NMR spectroscopy to differentiate between [4,5-13C]
and [4-13C]glutamate (Fig. 2D). In the 13C NMR spectrum,
glycolysis-derived [4,5-13C]glutamate is represented as a dou-
blet in the C-4 region of glutamate (34.5 ppm), whereas
PPP-derived [4-13C]glutamate is represented as a singlet. The
contribution of glucose metabolized via the PPP relative to
glucose metabolized via glycolysis to the total glutamate
synthesis was calculated by dividing the area of the
[4-13C]glutamate peak (after correction for natural abundance
using 1H NMR spectroscopy) by the area of the doublet
peak [4,5-13C]glutamate. We found that 106 0.2% (mean-
6 s.e.m.; n5 3) of the total glutamate comes from glucose
metabolized in the PPP. Our results confirm that the PPP is
active in oligodendrocytes and that it contributes to glutamate
synthesis.
Evidence for PDH and Mitochondrial Activity
in Oligodendrocytes
To investigate the extent of oxidative metabolism in oligoden-
drocytes, cells were incubated with 13C-labelled glucose or
[1,2-13C]acetate for 24 h (for labelling patterns, see Fig. 3A,
B). We confirmed that after 24 h, all [1,6-13C]glucose-derived
metabolites, except for glutamine, reached a steady-state of
labelling (Supp. Info. Fig. 1). Hence, we decided to investi-
gate labelling patterns in cell lysates after 24 h in all subse-
quent experiments. Assessing cell viability using TUNEL
staining showed no differences between the various experi-
mental conditions (Fig. 3C). Metabolism of [1,6-13C]glucose
yields two molecules of [3-13C]alanine and [3-13C]pyruvate.
The latter is then converted into [2-13C]acetyl CoA, which
can condense with nonlabelled oxaloacetate to form monola-
belled (M11) compounds in the first turn of the TCA cycle
(described in Fig. 3A). [2-13C]acetyl CoA can also condense
with labelled oxaloacetate and give rise to the formation of
double-labelled (M12) compounds in a combination of the
first and second turn of the cycle (Fig. 3A). GC–MS analysis
of cell extracts incubated with [1,6-13C]glucose (Fig. 3D),
showed that mitochondrial metabolism was prominent in
mature oligodendrocytes. TCA cycle intermediates and amino
acids were highly enriched ranging from 15 to 25% in citrate,
malate, glutamate, and glutamine and 10% in aspartate (Fig.
3D). Moreover, a substantial enrichment was also observed
with M12 isotopologues and even M13 (data not shown),
typical of the second and third turns of the TCA cycle (see
Fig. 3D). However, the second turn of the TCA cycle is
underestimated since labelled oxaloacetate can condense with
unlabelled acetyl CoA and give rise to single labelled (M11)
compounds in the second turn. Second turn isotopologues
were also observed when [1,2-13C]glucose was used as sub-
strate (Fig. 3D). It is important to note that only half of the
pyruvate molecules are labelled from [1,2-13C]glucose and,
therefore, the maximum enrichment levels will be half of
those obtained from [1,6-13C]glucose. Alanine is obtained
from pyruvate transamination and is generally considered to
be a metabolite related to glycolysis. The expected isotopo-
logue of [1,2-13C]glucose is [1,2-13C]alanine. However, we
observed M11 alanine in addition to M12-labelled alanine
(Fig. 3D). This is evidence for the presence of partial pyru-
vate recycling, which can be performed via decarboxylation of
malate or oxaloacetate into pyruvate (Sonnewald, 2014).
Acetate Metabolism in Oligodendrocytes
Conversion of acetate into acetyl CoA is known to take place
in astrocytes, but not in neurons (Sonnewald and Rae, 2010).
To investigate whether oligodendrocytes are able to convert
acetate into acetyl CoA and oxidize it in the TCA cycle, cells
were incubated with [1,2-13C]acetate for 24 h and the extra-
and intracellular metabolites were analyzed by GC–MS (Fig.
3B, D). Both [1,2-13C]acetate and [1,2-13C]glucose identically
yield [1,2-13C]acetyl CoA (Fig. 3B). Overall, the extent of
labelling from [1,2-13C]acetate was much lower than that from
[1,2-13C]glucose. Enrichment of the most abundant metabo-
lites citrate and glutamate from [1,2-13C]acetate was approxi-
mately half of enrichment obtained from [1,2-13C]glucose; the
less-abundant metabolites, aspartate and glutamine, were
poorly enriched. The abundance of M11 isotopologues (typi-
cal of the second turn of the TCA cycle) derived from
[1,2-13C]acetate was very low (Fig. 3D), suggesting that
acetate-derived acetyl CoA is metabolized in a different com-
partment than pyruvate-derived acetyl CoA. Alanine enrich-
ment from [1,2-13C]acetate (albeit at low levels), confirms that
oligodendrocytes have active partial pyruvate recycling, as
observed in cells incubated with [1,2-13C]glucose. In the
medium, labelling from [1,2-13C]acetate was only detectable
in citrate, in which M12 amounted to 106 2% (mean-
6 s.e.m., n5 12).
Glucose Consumption and Release of Metabolites
to the Culture Medium
Analysis of glucose consumption and lactate release rates (Fig.
3E-I, II) indicates that oligodendrocytes metabolize glucose to
an extent comparable to astrocytes (3.26 0.06 mmol/106
cells/24 h; mean6 s.e.m.; n5 6). However, oligodendrocytes
release less lactate than astrocytes (5.36 0.16 mmol/106 cells/
24 h; mean6 s.e.m.; n5 6). Although glucose consumption
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FIGURE 3: Evidence of high TCA cycle activity and acetate metabolism in mature oligodendrocytes in culture. Oligodendrocytes were dif-
ferentiated for 5 days and incubated for 24 h in medium containing [1,6-13C]glucose (A), [1,2-13C]glucose (B), or [1,2-13C]acetate (B), fol-
lowed by GC–MS analysis of samples of cell culture medium and cell extracts. A and B describe the labelling patterns deriving from the
metabolism of these 13C-labelled substrates. The isotopologues formed in the second turn of the TCA cycle result from condensation of
labelled oxaloacetate (OAA) with labelled or unlabelled acetyl CoA. (C) Quantification of TUNEL positive/total cell number (given by DAPI
staining) in cells incubated with glucose alone (mean6 s.e.m., n512), glucose and lactate (mean6 s.e.m., n510), or acetate (mean-
6 s.e.m., n58); (D) % enrichment of 13C in intracellular alanine and TCA cycle-related metabolites derived from each of the substrates
(mean6 s.e.m., n58 for [1,6-13C]glucose, mean6 s.e.m., n56 for [1,2-13C]glucose and mean6 s.e.m., n512 for [1,2-13C]acetate). (E) Glu-
cose (I) and lactate (II) net change in the medium in experiments performed in the presence of glucose alone or glucose1 [1-13C]lactate.
For the experiment where [1-13C]lactate was used, the net change of 13C-labelled and unlabelled lactate is shown (III) (mean6 s.e.m.,
n59). #—significantly different from the glucose1 [1-13C]lactate group (P<0.05, Student’s t-test). Abbreviations: ALA, alanine; ASP, aspar-
tate; CIT, citrate; GLN, glutamine; GLU, glutamate; MAL, malate; PYR, pyruvate; M11, parent ion with one 13C atom; M12, parent ion
with two 13C atoms; M13, parent ion with three 13C atoms; M14, parent ion with four 13C atoms. *The enrichment detected in alanine
derives directly from 13C-labelled pyruvate and not from the TCA cycle when [1,6-13C]glucose is the precursor. When [1,2-13C]glucose is
used, M12 is not derived from the TCA cycle but M11 alanine is. When [1,2-13C]acetate is in the medium, both alanine isotopologues are
derived from the TCA cycle. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
in the presence of 4 mM [1-13C]lactate (Fig. 3E-I) was
increased, the net release of total lactate remained unchanged
(Fig. 3E-II). Due to the presence of [1-13C]lactate in the cul-
ture medium, it was possible to distinguish between the
uptake of [1-13C]lactate and the release of endogenous (unla-
belled) lactate (Fig. 3E-III). This analysis showed that the
presence of lactate in the medium increased the release of
endogenous lactate (Fig. 3E-III). The release of unlabelled
lactate was at least 3-fold larger than the amount of
[1-13C]lactate consumed. By comparing lactate release rates
and glucose consumption rates, it was possible to estimate the
fraction of glucose metabolized to lactate, versus the oxidation
of pyruvate in the mitochondria. In oligodendrocytes cultured
with glucose alone, the ratio of lactate production to pyruvate
oxidation was 60:40 (and 80:20 in astrocytes). In the pre-
sence of lactate, the ratio changed to 30:70, indicating
increased mitochondrial activity. Figure 3C shows that the
viability of cells was not affected by the presence of lactate.
Despite the substantial % enrichment of 13C in the
aforementioned amino acids observed in the cell extracts,
only negligible release of alanine and glutamine was detected
(data not shown).
Pyruvate Carboxylation in Oligodendrocytes
Pyruvate carboxylation is an important anaplerotic pathway
known to operate in astrocytes but not in neurons (McKenna
et al., 2012). The presence of this pathway was probed in
mature oligodendrocytes using either [1,2-13C]glucose or
[1-13C]lactate (Fig. 4). [1-13C]lactate is a valuable substrate
for this purpose since only via pyruvate carboxylation the 13C
label from [1-13C]lactate can be found in the TCA cycle
intermediate citrate (PDH removes carbon number 1 from
pyruvate generating unlabelled acetyl CoA, and therefore, the
13C label is lost via PDH; Fig. 4A). In order to evaluate the
significance of pyruvate carboxylation in oligodendrocytes,
also astrocytes (the cells known to carboxylate pyruvate in the
brain) were incubated with [1-13C]lactate. Both of these cell
types were shown to oxidize lactate to a large extent in cul-
ture (Sanchez-Abarca et al., 2001). [1-13C]Pyruvate carboxyla-
tion was apparent in the labelling of citrate in the medium in
both cell types (Fig. 4B). However, in the cell extracts, this
was only evident in astrocytes. A possible explanation for the
FIGURE 4: [1-13C]lactate metabolism and evidence for pyruvate car-
boxylation in oligodendrocytes. (A) Labelling patterns resulting
from the metabolism of [1-13C]lactate (13C atoms are identified as
filled circles): [1-13C]lactate (LAC) is converted into [1-13C]pyruvate,
which can be converted into acetyl CoA via PDH or into [1-13C]oxalo-
acetate (OAA) via pyruvate carboxylase (PC). The first carbon of
pyruvate is lost in its conversion to acetyl CoA via PDH. Therefore,
the 13C label can only be observed downstream of pyruvate if PC is
active. [1-13C]oxaloacetate can condense with acetyl CoA to form
[6-13C]citrate, which also leads subsequently to the formation of
unlabelled a-ketoglutarate by loss of carbon 6. (B) The % enrichment
of 13C in citrate indicates the contribution of pyruvate carboxylation
to citrate formation from [1-13C]lactate. The % of M11 citrate was
assessed using GC–MS in samples of cell extracts and culture
medium from differentiated oligodendrocytes and also in cultures
of cortical astrocytes after 24 h of incubation with [1-13C]lactate (oli-
godendrocytes—mean6 s.e.m., n59; and astrocytes—mean-
6 s.e.m., n56). (C) Contribution of pyruvate carboxylation to
glutamate synthesis from [1,2-13C]glucose. Oligodendrocytes were
incubated in medium containing [1,2-13C]glucose for 24 h,
extracted, and analyzed using 13C-magnetic resonance spectros-
copy for the presence of isotopologues of glutamate formed via
pyruvate carboxylation. The C-2 region of glutamate (GLU) at 55.5
ppm is shown. The doublet representing [2,3-13C]glutamate is
formed via pyruvate carboxylation and the doublet representing
[1,2-13C]glutamate is formed via pyruvate dehydrogenation. Abbre-
viations: ASP, aspartate; GLN, glutamine; GLU, glutamate; MAL,
malate; OAA, oxaloacetate; PC, pyruvate carboxylase; PDH, pyru-
vate dehydrogenase; PYR, pyruvate. [Color figure can be viewed in
the online issue, which is available at wileyonlinelibrary.com.]
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absence of intracellular citrate enrichment in oligodendrocytes
is a potential compartmentation of pyruvate metabolism,
which has also been shown for astrocytes and neurons (Bak
et al., 2007; Bakken et al., 1997).
To further investigate the presence of pyruvate carboxy-
lation, oligodendrocytes were also incubated with medium
containing [1,2-13C]glucose. The C-2 region of glutamate
(around 55.5 ppm) in the 13C NMR spectrum of cell extracts
was analyzed to confirm the presence of pyruvate carboxyla-
tion (Fig. 4C). From the scheme depicted in Fig. 4C, it
emerges that only pyruvate carboxylation will lead to the for-
mation of [2,3-13C]glutamate, whereas [1,2-13C]glutamate
(and [3-13C]glutamate, which is not shown) is formed from
pyruvate dehydrogenation (and pyruvate carboxylation, if the
label stays in the cycle for an additional turn). The spectrum
shown in Fig. 4C, which reflects the presence of [2,3-13C]glu-
tamate, indicates that oligodendrocytes carboxylate pyruvate.
Discussion
Although oligodendrocytes make up a significant proportion
of brain cells, their metabolic properties remain largely
unknown. In a recent review, we have called for a systematic
study of metabolic pathways in oligodendrocytes (Amaral
et al., 2013). In this work, we study aspects of glucose, lactate,
and acetate metabolism in oligodendrocytes, and specifically
address the activity of the PPP and whether oligodendrocytes
are able to conduct anaplerotic and cataplerotic reactions based
on carboxylation of pyruvate and decarboxylation of malate or
oxaloacetate.
Primary rat OPCs were purified from perinatal rat-mixed
glial cultures (McCarthy and de Vellis, 1980). This approach
results in high yields of relatively pure (>93%) cultures. Cul-
ture of the O41, A2B51, O1-, CNP-, and MBP- OPCs in
Sato’s medium triggers a highly predictable series of morpho-
logical and transcriptional events and results in the formation
of mature oligodendrocytes with complex-branched processes
and membrane sheets, which express late stage markers, inclu-
ding MBP. Although a significant proportion of cells (approxi-
mately 60%) reach a mature oligodendrocyte stage, the
cultures also include late stage progenitors. Genomic studies
comparing acutely isolated cells at distinct developmental
stages with the culture system used in this study confirmed
that primary OPC cultures faithfully represent their in vivo
counterparts (Dugas et al., 2006).
Our results demonstrate that oligodendrocytes have
extensive glucose-derived metabolism. In fact, we found that
the rate of glucose consumption in oligodendrocytes is com-
parable to the one in astrocytes. Although Sanchez-Abarca
et al. (2001) previously concluded that oligodendrocytes use
more glucose than astrocytes, they also showed that oligoden-
drocytes metabolize a larger proportion of glucose via PDH
than astrocytes. We obtained a similar result by comparing
the ratios of lactate release to glucose consumption in both
cell types. Furthermore, we observed that both glucose con-
sumption and the proportion of glucose-derived pyruvate
metabolized in the mitochondria were increased in the pre-
sence of exogenous lactate. This suggests that lactate may act
as metabolic activator in oligodendrocytes, fitting with the
concept that lactate can act as signalling molecule (Rinholm
and Bergersen, 2014). Furthermore, our results confirm that
oligodendrocytes are able to release substantial amounts of
lactate in vitro as has been reported in vivo by Funfschilling
et al. (2012). Also, it is possible that, at least, a proportion of
the [1-13C]lactate taken up was oxidized for lipogenesis, as
proposed by (Sanchez-Abarca et al., 2001). In spite of the
presence of 4-mM exogenous lactate, a net production of lac-
tate was observed indicating that glycolysis in oligodendro-
cytes is not inhibited by extracellular lactate.
The PPP is a glucose shunt, which is thought to be
active in neurons and astrocytes (Almeida et al., 2002; Amaral
et al., 2010; Bolanos and Almeida, 2010; Brekke et al., 2012;
Garcia-Nogales et al., 2003). Using 14C tracing techniques,
Edmond et al. (1987) showed active PPP in oligodendrocyte
lineage cells. Sanchez-Abarca et al. (2001) reported PPP acti-
vity in immature OPC cultures as being 2-fold higher than in
astrocytes and 4-fold higher than in neurons. Our approach
measured the contribution of the PPP to the synthesis of gly-
colytic intermediates and glutamate synthesis based on 13C-
tracing techniques. In our study, the labelling of the glycolytic
intermediates PEP and 3PG indicate that mature oligoden-
drocytes use approximately 10–15% of glucose in the PPP
compared with glycolysis. These values are in the range of
previously published data for cortical astrocyte cultures in a
metabolic modelling study also using 13C-labelled substrates
(Amaral et al., 2011a), which contrasts with the report by
Sanchez-Abarca et al. (2001). It is possible that our cultures
contain more mature oligodendrocytes than those used by
Sanchez-Abarca et al., and therefore, have a lower PPP acti-
vity, more closely resembling the rate in astrocytes. On the
basis of 14C tracing experiments, Sykes et al. (1986) reported
that, although the PPP oxidizes only <3% of the glucose
consumed, it produces more CO2 than the TCA cycle in pri-
mary oligodendrocyte lineage cells, due to its close link to de
novo synthesis of fatty acids and cholesterol. Since we did not
measure the contribution of glucose to lipid synthesis, it is
possible that our approach underestimated the total use of
glucose via the PPP.
For the first time, our experiments demonstrate that
pyruvate generated from glucose via the PPP contributes to
the synthesis of acetyl CoA for oxidation and generation of
metabolites in the TCA cycle in oligodendrocytes. We found
that approximately 10% of the glutamate produced derives
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from glucose metabolized in the PPP. Estimation of the PPP
activity on the basis of glutamate isotopomers indicated that
the PPP accounted for approximately 6% of glucose metabo-
lism in cortical neurons and approximately 4% in cerebellar
neurons (Brekke et al., 2012). Similar to reports in neurons
(Brekke et al., 2012), we found that oligodendrocytes incor-
porate 13C label in glutamate produced by [1,2-13C]glucose
metabolism via the PPP.
The PPP may also play a role in diseases that affect oli-
godendrocytes. For example, increased activity of the transal-
dolase, an enzyme which forms part of the nonoxidative
branch of the PPP and is involved in lipid and nucleotide
synthesis, has been reported in oligodendrocytes in brains of
MS patients, compared with healthy controls (Banki et al.,
1994). NADPH produced in the PPP is fundamentally
important for the synthesis of glutathione, which is thought
to protect myelin sheaths from oxidative stress. Banki and
colleagues proposed that autoantibodies against transaldolase
found in MS patients, may cause destruction of oligodendro-
cytes via depletion of transaldolase. Altered PPP activity was
also reported in a study of patients that suffered a traumatic
brain injury (TBI; Dusick et al., 2007). It is possible that, at
least, a proportion of the PPP alterations observed in the
study by Dusick et al. (2007) could be linked to the extensive
demyelination that is thought to occur in TBI patients (Arm-
strong et al., in press).
Using different forms of 13C-labelled glucose, we de-
monstrate that our cultures also exhibit a high rate of mito-
chondrial metabolism, as previously suggested by Sanchez-
Abarca et al. (2001). Whereas functional mitochondria seem
to be important for OPC differentiation (Schoenfeld et al.,
2010; Ziabreva et al., 2010), it was recently proposed that
myelinating oligodendrocytes are not dependent on mito-
chondrial activity in vivo (Funfschilling et al., 2012). The
most likely explanation for the discrepancy between the high
mitochondrial demands of our cultures and the findings in
vivo is the significant presence of premyelinating (MBP-nega-
tive) OPCs that have not yet reached fully mature stages in
vitro. Our data thus may reflect the prominent role of oxida-
tive metabolism at the late stages of OPC differentiation,
including the premyelinating and early myelinating stages.
Another important question with respect to mitochon-
drial metabolism in oligodendrocytes is whether they can
replenish TCA cycle intermediates via anaplerosis. It is well
established that neurons depend on astrocytes for replenishing
their TCA cycle intermediates. As neurons cannot carboxylate
pyruvate, external TCA cycle intermediates are required for
the synthesis of amino acid neurotransmitters (McKenna
et al., 2012). Whether and to which extent oligodendrocytes
are self-sufficient with respect to the production of anaple-
rotic substrates remained unknown. By incubating cells with
[1,2-13C]glucose, we found that pyruvate carboxylation
indeed takes place in oligodendrocytes as shown by the produc-
tion of [2,3-13C]glutamate. This was further confirmed by label
incorporation in citrate in the medium of cells incubated with
[1-13C]lactate, which is only possible via pyruvate carboxylation.
Comparable label incorporation from [1-13C]lactate was found
in citrate in the medium of astrocyte cultures. This suggests that
lactate is metabolized in a similar way in the TCA cycle of both
cell types. However, it is possible that a fraction of the lactate
taken up by our cultures was used for lipogenesis (Sanchez-
Abarca et al., 2001). It must also be noted that the overall con-
tribution of pyruvate carboxylation to oligodendrocyte and
astrocyte metabolism is underestimated in the experiments
based on [1-13C]lactate metabolism because [1-13C]pyruvate
derived from [1-13C]lactate competes with unlabelled pyruvate
derived from glucose, which is also present in the incubation
medium.
Pyruvate can be carboxylated to oxaloacetate by PC or
to malate and NADP1 by malic enzyme. Whether PC or
malic enzyme is responsible for pyruvate carboxylation in oli-
godendrocytes remains to be established. Murin et al. (2009)
reported PC expression in cultured oligodendroglia. Whether
oligodendrocytes express malic enzyme remains unknown. In
neurons and astrocytes, malic enzyme only contributes to
pyruvate production (McKenna et al., 1995, 2000). However,
PC is thought to be the most important anaplerotic enzyme
in the brain (Patel, 1974). Irrespective of which enzyme is
responsible for pyruvate carboxylation, the detection of car-
boxylation (and thus anaplerosis) has consequences for oligo-
dendrocyte metabolism. If oligodendrocytes (similarly to
neurons) were not capable of anaplerosis, they would depend
on the provision of glutamine by astrocytes, which have a net
production of glutamine via pyruvate carboxylation (Gamber-
ino et al., 1997; Waagepetersen et al., 2001).
An alternative route to replenish the TCA cycle in oli-
godendrocytes is to use aspartate, liberated from N-acetyl
aspartate (NAA), which in turn is supplied by neurons (Mof-
fett et al., 2007). However, aspartate released by NAA hydro-
lysis in oligodendrocytes could potentially be sent back to
neurons, thus avoiding the depletion of anaplerotic substrates
in neurons (NAA synthesis in neurons is dependent on gluta-
mine entry from astrocytes). Our results indicate that oligo-
dendrocytes are capable of anaplerosis, which suggests that
they are potentially independent of astrocytic pyruvate car-
boxylation. Whether the level of anaplerosis in oligodendro-
cytes is sufficient to meet their entire requirements is not
known at present. It is also unclear whether aspartate is shut-
tled back to neurons or whether it is metabolized in oligoden-
drocytes. Both possibilities have previously been suggested but
evidence is lacking (Baslow and Guilfoyle, 2006; Moffett
et al., 2007).
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Acetyl CoA is an essential molecule in the TCA cycle.
Most acetyl CoA derives from pyruvate via PDH. However,
oligodendrocytes are known to express the enzyme aspartoacy-
lase, which catalyzes the hydrolysis of NAA into aspartate and
acetate (Moffett et al., 2011). NAA-derived acetate signifi-
cantly contributes to myelin lipid synthesis in the CNS
(Chakraborty et al., 2001) and is also thought to support oxi-
dative metabolism during myelination (Francis et al., 2012).
Furthermore, oligodendrocytes express acetyl CoA synthetase-
1, which catalyzes the synthesis of acetyl coenzyme A from
acetate and coenzyme A, indicating that acetate may contrib-
ute to lipid synthesis, especially during postnatal brain deve-
lopment (Ariyannur et al., 2010). So far only astrocytes were
shown to convert acetate into acetyl CoA whereas neurons do
not seem able to do so (Muir et al., 1986; Sonnewald et al.,
1993a). Consequently, acetate has been used extensively to
assess astrocyte metabolism in the context of astrocytic-
neuronal interactions in vivo (e.g., Melo et al., 2005; Morken
et al., 2014; Nilsen et al., 2014), in neurospheres (Sa Santos
et al., 2011), and in culture (Sonnewald et al., 1993a). How-
ever, potential metabolic contributions from oligodendrocytes
were not considered in these studies. This work demonstrates
that mature oligodendrocyte cultures are able to convert ace-
tate into acetyl CoA and oxidize it in the mitochondria as
shown by the incorporation of 13C label from [1,2-13C]ace-
tate into the TCA cycle intermediates malate and citrate and
the amino acids glutamate and glutamine. Labelling from
[1,2-13C]acetate was not as pronounced as labelling from
[1,2-13C]glucose but, nevertheless, significant and comparable
to that observed in astrocytes (data not shown). However,
astrocytes label glutamine extensively from 13C-labelled ace-
tate (Hassel et al., 1995), whereas oligodendrocytes do not.
Surprisingly, we found that alanine was also labelled from
[1,2-13C]acetate, and that alanine M11 enrichment was
detected in oligodendrocytes incubated with [1,2-13C]glucose.
Both isotopologues of alanine could not have been produced
without the participation of the TCA cycle and malic enzyme
or pyruvate kinase and phosphoenolpyruvate carboxykinase
FIGURE 5: Integration of metabolic pathways operating in oligodendrocytes in the context of metabolic interactions with astrocytes and
neurons/axons. The pathways investigated in this study are highlighted in red in the oligodendrocyte: glucose is taken up and subse-
quently metabolized either via glycolysis only (1) or also via the pentose phosphate pathway (2); the resulting pyruvate (PYR) produced
can be reduced to lactate (LAC) (3) which can be released and taken up by cells with lower lactate concentration. Moreover, pyruvate
can be carboxylated via PC or malic enzyme (ME) into oxaloacetate (OAA) or malate (MAL) or enter the TCA cycle after being converted
to acetyl CoA (Ac-CoA) via PDH (4). The TCA cycle intermediate a-ketoglutarate (a-KG) gives rise to glutamate (GLU) and, subsequently,
glutamine (GLN), but none of these aminoacids appear to be significantly released. Pyruvate can be further completely oxidized if it is
decarboxylated via ME, a pathway called pyruvate recycling (5), which also seems to be present in this cell type. Oligodendrocytes can
also metabolize acetate into acetyl CoA (6) that can be then incorporated into lipids or oxidized in the TCA cycle. [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
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(Cruz et al., 1998). This indicates that pyruvate recycling, a
catabolic pathway (Amaral et al., 2011b; Cerdan et al., 1990;
Haberg et al., 1998; Kunnecke et al., 1993; Olstad et al.,
2007), is not only active in astrocytes and neurons but also in
oligodendrocytes.
Conclusion
Our results show that oligodendrocyte lineage cells at late
stages of differentiation are metabolically active cells and have
distinct metabolic properties. We found that the cells were
able to conduct all the metabolic functions that were investi-
gated and, therefore, demonstrate a high degree of cellular
independence. Figure 5 summarizes the findings of the pre-
sent series of experiments and integrates our data with the
known pathways linking astroglial and neuronal metabolism.
Our results indicate that metabolic functions of oligodendro-
glia need to be considered in studies investigating glucose
metabolism in CNS tissue or whole brain studies. This work
reinforces the emerging role of oligodendrocyte metabolism
with respect to neuronal–glial interactions.
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